-
Effective marketing needed to ensure uptake of Merck's newest HPV vaccine, report finds
LONDON — An experimental human papillomavirus vaccine made by Merck could offer a boost to the vaccine market, but the company will have to use effective marketing efforts to ensure uptake, according to a new study.
The London-based research and consulting firm GlobalData said Merck's V503 vaccine, currently in phase-3 clinical trials, had strong potential because it protects against five HPV types not covered by current vaccines and demonstrates 97% efficacy against precancerous lesions caused by the additional virus types it contains.
-
FDA advisory committee recommends approval of Vanda Pharmaceuticals' Hetlioz for non-24-hour disorder in the totally blind
WASHINGTON — A Food and Drug Administration expert panel has voted to recommend approval for a drug to treat a circadian rhythm disorder that affects most people with total blindness.